Lupin Launches Ganirelix Acetate Injection in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix Acetate Injection had estimated annual sales of USD 87 million in the U.S. (IQVIA MAT December 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1609.60 as compared to the previous close of Rs. 1608.05. The total number of shares traded during the day was 15372 in over 1261 trades.

The stock hit an intraday high of Rs. 1617.45 and intraday low of 1590.90. The net turnover during the day was Rs. 24642116.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 GanirelixAcetateInjection USA